Concurrent Chemoradiotherapy Should Remain Standard of Care for Locally Advanced NSCLC
Concurrent chemoradiotherapy should remain as standard of care for treatment of locally advanced non-small cell lung cancer (NSCLC).
Diagnosis & Disease Information
Final OS Results from the Phase 3 OPTIMAL Trial in EGFR-Positive NSCLC
Final results from OPTIMAL trial showed that patients with mutant type EGFR showed significant survival benefit when treated with erlotinib.
Anabolic Response of Essential Amino Acid Mixtures in Advanced Lung Cancer
Dietary essential amino acids could have a key role in novel nutritional approaches in prevention of muscle loss in patients with cancer.
Postoperative Radiotherapy May Improve Survival in Incompletely Resected Lung Cancer
Postoperative radiotherapy associated with improved overall survival in incompletely resected non-small cell lung cancer (NSCLC).
Radiofrequency Ablation Safe, Effective in Medically Inoperable Lung Cancer
Radiofrequency ablation is well tolerated in medically inoperable patients with stage IA non-small cell lung cancer (NSCLC).
BRAF mutations in non-small cell lung cancer
[Translational Lung Cancer Research] This research investigates the prevalence and clinicopathological features of BRAF mutations in non-small cell lung cancer (NSCLC) cases submitted for routine mutation testing.
EGFR Mutations Most Prevalent in Women with Adenocarcinoma, No Smoking History
Certain baseline characteristics show greater epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC).
Cisplatin-Based Doublet May Improve Survival in Relapsed Lung Cancer
Docetaxel plus cisplatin improved overall survival in patients with resected non-small cell lung cancer (NSCLC) relapsing.
In Lung Cancer, Afatinib Active in Certain Uncommon EGFR Mutations
Afatinib has activity against non-small cell lung carcinoma (NSCLC) tumors that harbor certain uncommon mutations.
Results of Nivolumab CheckMate 057 Study May Change Treatment of Lung Cancer
Options for treatment of patients with non-squamous non-small cell lung cancer (NSCLC) who progress after initial therapy are limited.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...